Concepedia
Statistics
Publications
5
Citations
99
H-Index
Active since
2014
Affiliations
AstraZeneca (Sweden)(Current)
Health Economics and Outcomes Research (United Kingdom)
Swansea University
Uppsala University
U. Sabale is an author at AstraZeneca (Sweden) specializing in diabetes, public health, and health economics.
Top concepts
DiabetesMedicineHealth PolicyPublic HealthHealth EconomicsPrimary CareGlobal HealthFamily MedicinePharmacotherapyEconomic Evaluation
Publications per year
2014–2017
Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
U. Sabale, Mattias Ekman, Ola Granström et al. · Primary care diabetes · 2014 · 39 citations
Diabetes Management, Health Policy, Health Economics +9
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting
U. Sabale, Johan Bodegård, Johan Sundström et al. · Primary care diabetes · 2015 · 19 citations
Family Medicine, Diabetes Management, Primary Care +12
Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014
David Nathanson, U. Sabale, Jan W. Eriksson et al. · PharmacoEconomics - Open · 2017 · 16 citations · Full text
Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
U. Sabale, Mattias Ekman, Daniel Thunström et al. · PharmacoEconomics - Open · 2017 · 15 citations · Full text
The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes
Jason Gordon, P McEwan, U. Sabale et al. · Journal of Medical Economics · 2016 · 10 citations
1–5 of 5